RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1 - PD-L1 and VEGF - VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer [1] [2].
In Vitro, RC148 inhibits VEGF-VEGFR and PD-1-PD-L1 binding, suppresses human umbilical vein endothelial cell growth and migration, and efficiently activates T cells[1].
References:
[1]. Fang JM, et al. Abstract 2734: RC148, a novel bispecific antibody targeting PD-1 and VEGF for cancer immunotherapy. Cancer Res. 2024 Mar 24;84(6_Supplement);2734.
[2]. Wang JY, et al. Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study. J Clin Oncol. 2025 May 28; 43(16_suppl):TPS1139.
In Vitro, RC148 inhibits VEGF-VEGFR and PD-1-PD-L1 binding, suppresses human umbilical vein endothelial cell growth and migration, and efficiently activates T cells[1].
References:
[1]. Fang JM, et al. Abstract 2734: RC148, a novel bispecific antibody targeting PD-1 and VEGF for cancer immunotherapy. Cancer Res. 2024 Mar 24;84(6_Supplement);2734.
[2]. Wang JY, et al. Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study. J Clin Oncol. 2025 May 28; 43(16_suppl):TPS1139.